These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 36455692

  • 1. Evaluation of Body Composition in Patients With and Without Adrenal Tumors and Without Overt Hypersecretory Syndromes.
    Araujo-Castro M, Pascual-Corrales E, García Cano AM, Marchan M, Casals G, Hanzu FA, Gomez-Bermejo MÁ, Escobar Morreale HF, Valderrabano P.
    Endocr Pract; 2023 Feb; 29(2):110-118. PubMed ID: 36455692
    [Abstract] [Full Text] [Related]

  • 2. Characterisation of the urinary steroid profile of patients with nonfunctioning adrenal incidentalomas: A matched controlled cross-sectional study.
    Araujo-Castro M, Casals G, Hanzu FA, Pascual-Corrales E, García Cano AM, Lanza VF, Luis Del Rey Mejías Á, Marchan M, Escobar-Morreale HF, Valderrabano P.
    Clin Endocrinol (Oxf); 2023 Feb; 98(2):165-176. PubMed ID: 35973974
    [Abstract] [Full Text] [Related]

  • 3. Is the 1mg-dexamethasone suppression test a precise marker of glucocorticoid excess and cardiometabolic risk in patients with adrenal incidentalomas?
    Araujo-Castro M, Hanzu FA, Pascual-Corrales E, García Cano AM, Marchan M, Escobar-Morreale HF, Valderrabano P, Casals G.
    Endocrine; 2023 Oct; 82(1):161-170. PubMed ID: 37351760
    [Abstract] [Full Text] [Related]

  • 4. Adrenal steroid metabolites and bone status in patients with adrenal incidentalomas and hypercortisolism.
    Nakao H, Yokomoto-Umakoshi M, Nakatani K, Umakoshi H, Ogata M, Fukumoto T, Kaneko H, Iwahashi N, Fujita M, Ogasawara T, Matsuda Y, Sakamoto R, Izumi Y, Bamba T, Ogawa Y.
    EBioMedicine; 2023 Sep; 95():104733. PubMed ID: 37543511
    [Abstract] [Full Text] [Related]

  • 5. Nonfunctioning adrenal incidentalomas with cortisol post-dexamethasone suppression test >0.9 µg/dL have a higher prevalence of cardiovascular disease than those with values ≤0.9 µg/dL.
    Araujo-Castro M, Parra Ramírez P, Martín Rojas-Marcos P, García Centeno R, Gracia Gimeno P, Tomé Fernández-Ladreda M, Sampedro Núñez MA, Higueruela C, Robles Lázaro C.
    Endocrine; 2023 Feb; 79(2):384-391. PubMed ID: 36261701
    [Abstract] [Full Text] [Related]

  • 6. Clinical features, risk of mass enlargement, and development of endocrine hyperfunction in patients with adrenal incidentalomas: a long-term follow-up study.
    Falcetta P, Orsolini F, Benelli E, Agretti P, Vitti P, Di Cosmo C, Tonacchera M.
    Endocrine; 2021 Jan; 71(1):178-188. PubMed ID: 32915435
    [Abstract] [Full Text] [Related]

  • 7. Cardiometabolic profile of non-functioning and autonomous cortisol-secreting adrenal incidentalomas. Is the cardiometabolic risk similar or are there differences?
    Araujo-Castro M, Robles Lázaro C, Parra Ramírez P, Cuesta Hernández M, Sampedro Núñez MA, Marazuela M.
    Endocrine; 2019 Dec; 66(3):650-659. PubMed ID: 31473918
    [Abstract] [Full Text] [Related]

  • 8. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates.
    Tsilchorozidou T, Honour JW, Conway GS.
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5907-13. PubMed ID: 14671189
    [Abstract] [Full Text] [Related]

  • 9. Visceral fat accumulation and postdexamethasone serum cortisol levels in patients with adrenal incidentaloma.
    Debono M, Prema A, Hughes TJ, Bull M, Ross RJ, Newell-Price J.
    J Clin Endocrinol Metab; 2013 Jun; 98(6):2383-91. PubMed ID: 23633207
    [Abstract] [Full Text] [Related]

  • 10. The Steroid Profile of Adrenal Incidentalomas: Subtyping Subjects With High Cardiovascular Risk.
    Di Dalmazi G, Fanelli F, Zavatta G, Ricci Bitti S, Mezzullo M, Repaci A, Pelusi C, Gambineri A, Altieri P, Mosconi C, Balacchi C, Golfieri R, Cosentino ER, Borghi C, Vicennati V, Pasquali R, Pagotto U.
    J Clin Endocrinol Metab; 2019 Nov 01; 104(11):5519-5528. PubMed ID: 31381072
    [Abstract] [Full Text] [Related]

  • 11. Autonomous cortisol secretion in adrenal incidentalomas and increased visceral fat accumulation during follow-up.
    Yener S, Baris M, Peker A, Demir O, Ozgen B, Secil M.
    Clin Endocrinol (Oxf); 2017 Nov 01; 87(5):425-432. PubMed ID: 28656620
    [Abstract] [Full Text] [Related]

  • 12. Accuracy of the dexamethasone suppression test for the prediction of autonomous cortisol secretion-related comorbidities in adrenal incidentalomas.
    Araujo-Castro M, Parra Ramírez P, Robles Lázaro C, García Centeno R, Gracia Gimeno P, Fernández-Ladreda MT, Sampedro Núñez MA, Marazuela M, Escobar-Morreale HF, Valderrabano P.
    Hormones (Athens); 2021 Dec 01; 20(4):735-744. PubMed ID: 34273083
    [Abstract] [Full Text] [Related]

  • 13. Study of glucose tolerance in consecutive patients harbouring incidental adrenal tumours. Study Group of Incidental Adrenal Adenoma.
    Fernández-Real JM, Engel WR, Simó R, Salinas I, Webb SM.
    Clin Endocrinol (Oxf); 1998 Jul 01; 49(1):53-61. PubMed ID: 9797847
    [Abstract] [Full Text] [Related]

  • 14. Predictors of Tumour Growth and Autonomous Cortisol Secretion Development during Follow-Up in Non-Functioning Adrenal Incidentalomas.
    Araujo-Castro M, Parra Ramírez P, Robles Lázaro C, García Centeno R, Gracia Gimeno P, Fernández-Ladreda MT, Sampedro Núñez MA, Marazuela M, Escobar-Morreale HF, Valderrabano P.
    J Clin Med; 2021 Nov 25; 10(23):. PubMed ID: 34884211
    [Abstract] [Full Text] [Related]

  • 15. Impact of hypercortisolism on skeletal muscle mass and adipose tissue mass in patients with adrenal adenomas.
    Delivanis DA, Iñiguez-Ariza NM, Zeb MH, Moynagh MR, Takahashi N, McKenzie TJ, Thomas MA, Gogos C, Young WF, Bancos I, Kyriazopoulou V.
    Clin Endocrinol (Oxf); 2018 Feb 25; 88(2):209-216. PubMed ID: 29115003
    [Abstract] [Full Text] [Related]

  • 16. Predictive model for autonomous cortisol secretion development in non-functioning adrenal incidentalomas.
    Araujo-Castro M, García Cano AM, Escobar-Morreale HF, Valderrabano P.
    Hormones (Athens); 2023 Mar 25; 22(1):51-59. PubMed ID: 36279032
    [Abstract] [Full Text] [Related]

  • 17. Adrenal incidentaloma: Do patients with apparently nonfunctioning mass or autonomous cortisol secretion have similar or different clinical and metabolic features?
    Rebelo JFD, Costa JM, Junqueira FD, Fonseca AO, de Almeida ABABS, Moraes AB, Vieira Neto L.
    Clin Endocrinol (Oxf); 2023 May 25; 98(5):662-669. PubMed ID: 36514987
    [Abstract] [Full Text] [Related]

  • 18. The low-dose dexamethasone suppression test in patients with adrenal incidentalomas: comparisons with clinically euadrenal subjects and patients with Cushing's syndrome.
    Tsagarakis S, Kokkoris P, Roboti C, Malagari C, Kaskarelis J, Vlassopoulou V, Alevizaki C, Thalassinos N.
    Clin Endocrinol (Oxf); 1998 May 25; 48(5):627-33. PubMed ID: 9666875
    [Abstract] [Full Text] [Related]

  • 19. Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver.
    Westerbacka J, Yki-Järvinen H, Vehkavaara S, Häkkinen AM, Andrew R, Wake DJ, Seckl JR, Walker BR.
    J Clin Endocrinol Metab; 2003 Oct 25; 88(10):4924-31. PubMed ID: 14557475
    [Abstract] [Full Text] [Related]

  • 20. Abnormal body composition in patients with adrenal adenomas.
    Delivanis DA, Hurtado Andrade MD, Cortes T, Athimulam S, Khanna A, Atkinson E, McKenzie T, Takahashi N, Moynagh MR, Bancos I.
    Eur J Endocrinol; 2021 Oct 08; 185(5):653-662. PubMed ID: 34406976
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.